Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?

•COVID-19 is a pandemic caused by the SARS-Cov-2 coronavirus.•The pneumonia caused by COVID-19 may cause high mortality.•Treatment and/or vaccination for virus is an ongoing proccess, they have not been discovered yet.•Interferons could be effective for the treatment of COVID-19.•Further studies of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis and related disorders 2020-07, Vol.42, p.102196, Article 102196
Hauptverfasser: Gemcioglu, Emin, Davutoglu, Mehmet, Ozdemir, Ese Ece, Erden, Abdulsamet
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•COVID-19 is a pandemic caused by the SARS-Cov-2 coronavirus.•The pneumonia caused by COVID-19 may cause high mortality.•Treatment and/or vaccination for virus is an ongoing proccess, they have not been discovered yet.•Interferons could be effective for the treatment of COVID-19.•Further studies of the experiences of people with MS who take type I interferons, such as beta interferons who get COVID-19, will help to inform. The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2020.102196